Quanterix Corporation to Present At 39th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present on the company's growth at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 p.m. EST. This marks Hrusovsky's fifth consecutive year presenting at this conference. The live webcast will be accessible for attendees and the public. Quanterix focuses on advancing precision health through digitizing biomarker analysis, aiming for earlier disease detection and improved treatment methodologies across multiple therapeutic areas, including oncology and neurology.
- None.
- None.
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company’s growth and vision for the fifth consecutive year at the 39th Annual J.P. Morgan Healthcare Conference, taking place virtually. Hrusovsky’s session will take place on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST (12:40 p.m., PST) and will be made available to attendees and public listeners here.
Webcast Information
To access the live webcast of Quanterix’ presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 3:40 p.m., EST, please visit: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35235-quanterix-corporation/webcast?gpu_only=true&kiosk=true.
Replays of the webcasts will be available for a limited period following the conference.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005838/en/
FAQ
When is Quanterix presenting at the J.P. Morgan Healthcare Conference?
Who is presenting for Quanterix at the J.P. Morgan Healthcare Conference?
What is the focus of Quanterix's presentation at the conference?
How can I access the Quanterix presentation webcast?
What technology does Quanterix use for biomarker analysis?
